The Effect of Exenatide on Fasting Bile Acids

The Effect of Exenatide on Fasting Bile Acids in Newly Diagnosed Type 2 Diabetes Mellitus Patients, a Pilot Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04303819

Enrollment

Registered

2020-03-11

Start date

2020-01-05

Completion date

2020-01-31

Last updated

2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus in Obese

Brief summary

Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were compared before and after exenatide treatment and correlation analysis between changes of FTBAs and glycemic parameters.

Detailed description

Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were tested at baseline. Then exenatide were applied to the T2DM participants for 12 weeks. FTBAs and glycemic parameters were measured again after exenatide treatment, and correlation analysis between changes of FTBAs and glycemic parameters were conducted to investigate the role of BAs in the glycemic control effect of exenatide.

Interventions

DRUGExenatide treatment

12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Newly diagnosed T2DM patients

Exclusion criteria

* History of hepatobiliary or pancreatic diseases * History of anti-diabetic drugs intake * Change of anti-dyslipidemia therapy regimen * Estimated glomerular filtration rate less than 60 mL/min/1.73 m\^2 * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Plasma total bile acids in fasting state	12 weeks	reported in μmol/L

Secondary

Measure	Time frame	Description
fasting plasma glucose	12 weeks	reported in mmol/L
Glycated hemoglobin A1c	12 weeks	reported in %
C-peptide	12 weeks	reported in mU/L
Fasting serum insulin	12 weeks	reported in mU/L
Body mess index	12 weeks	reported in kg/m\^2

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026